Janssen Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceuticals Inc.
While Operation Warp Speed is trying to harmonize coronavirus study designs, Pfizer’s go-it-alone approach may make its vaccine hard to compare to others.
The European Medicines Agency says that available evidence from a discontinued study does not call into question PharmaMar/Janssen’s Yondelis in its currently authorized uses. But in a separate recommendation it says that bioequivalence studies on generic drugs conducted by CRO Panexcell might be flawed.